Radiation therapy technology developer ViewRay announced that Centre Oscar Lambret has selected its MRIdian MRI-Guided Radiation Therapy System.

The centre will be the first in Lille, France, to provide the Hauts de France area with advanced MRI-guided radiation treatment equipment.

Centre Oscar Lambret works for the treatment and study of cancer with care, research, and teaching as its three primary objectives.

It places a premium on patient access to high-quality care and aims to expedite cancer advancements for all patients in the Hauts-de-France area.

ViewRay said that 151 clinical trials are now being conducted as part of the initiative, and the radiation treatment division sees around 3,500 patients annually.

The MRIdian system gives doctors anatomical vision through diagnostic-quality MR images and the capacity to modify a radiation therapy plan for the targeted malignancy with the patient on the table.

This combination enables the administration of ablative radiation doses in five or less treatment sessions without relying on implanted markers.

It also allows the doctors to establish tight treatment boundaries to prevent needless radiation exposure to fragile organs at risk and healthy tissue.

MRIdian permits automated radiation beam gating if the target wanders outside the user-defined boundaries by providing real-time continuous tracking of the target and organs at risk.

This reduces the toxicities associated with traditional treatment by giving a specified dosage to the target while preserving nearby healthy tissue and important structures, said ViewRay.

ViewRay chief medical officer Martin Fuss said: “We are pleased to welcome Centre Oscar Lambret to the MRIdian global community. With MRIdian, Centre Oscar Lambret will offer personalised treatment to a broader population of cancer patients.

“Through the use of MRI-guidance, on-table adaptive replanning capabilities, and the ability to control the radiation beam based on real-time MR-imaging during treatment, Centre Oscar Lambret will improve the accuracy with which they deliver radiation treatments.

“Patients will benefit from higher radiation doses delivered in fewer treatment sessions, even if they may have tumours that are today considered virtually untreatable.”